EUCTR2021-004137-36-BE进行中（未招募）1 期
Study of EOS884448 alone, and in combination with iberdomide with or without dexamethasone, in participants with relapsed or refractory multiple myeloma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 58
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Participants are eligible to be included in the study if all the following criteria are met:
- •1. Written informed consent signed in accordance with federal, local, and institutional guidelines, including consent for bone marrow aspirate (BMA) before and during administration of study treatment.
- •2. Age greater than or equal to (=) 18 years at the time of informed consent.
- •3. Documented diagnosis of MM.
- •4. Have received at least 3 prior lines of myeloma therapy including an IMiD, a proteasome inhibitor, and an anti-CD38 antibody in any order during the course of treatment for multiple myeloma (note: induction with or without bone marrow transplant and with or without maintenance therapy is considered one line) and not be candidate for regimens known to provide clinical benefit in this setting.
- •5. Must have progressed on their last line of myeloma therapy.
- •6. Measurable disease as defined by at least one of the following:
- •a. Serum M-protein = 0.5 gram per deciliter (g/dL) by serum protein electrophoresis (SPEP) or, for immunoglobulin A (IgA) myeloma, by quantitative IgA
- •b. Urinary M-protein of at least 200 mg/24 hours by urine protein electrophoresis (UPEP)
- •c. Serum free light chain (FLC) = 100 milligram per liter (mg/L), provided that FLC ratio is abnormal
- •d. If SPEP is felt to be unreliable for routine M-protein measurement (example, for IgA or IgD MM), then quantitative immunoglobulin (Ig) levels by nephelometry or turbidometry are acceptable
- •7. Any non-hematological toxicities that patients had from prior treatments must have resolved to less than or equal (=) Grade 1 by C1D1 with the exception of alopecia.
- •8. Eastern Cooperative Oncology Group (ECOG) Performance Status of = 2.
- •9. Adequate hepatic function within 28 days prior to C1D1: Total bilirubin < 2 X ULN (except patients with Gilbert's syndrome (hereditary indirect hyperbilirubinemia) who must have a total bilirubin of = 3 X ULN) and both AST and ALT = 2.5X ULN
- •10. Adequate renal function within 28 days prior to C1D1. Creatinine clearance (CrCl) > 45 mL per minute or greater using the formula of Cockroft and Gault (1976):
- •a. CrCl (female) = (([140-age] x weight in kg)/(serum creatinine x 72)) x 0.85;
- •b. CrCl (male) = ([140-age] x weight in kg)/(serum creatinine x 72)
- •11. Adequate hematopoietic function within 28 days prior to C1D1: total white blood cell count = 1,500/millimeter cube (mm^3), absolute neutrophil count (ANC) = 1,000/mm^3, hemoglobin = 8.0 g/dL. Platelet count = 75,000/mm^3 for Part 1. For Part 2: platelet count = 75,000/mm^3 for participants in whom < 50% of bone marrow nucleated cells are plasma cells, otherwise platelet count = 50,000/mm^3
- •12. Females of childbearing potential (FCBP) must:
- •a. Have two negative pregnancy tests as verified by the Investigator prior to starting study treatment. She must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment. This applies even if the participant practices true abstinence* from heterosexual contact.
- •b. Either commit to true abstinence* from heterosexual contact or agree to use, and be able to comply with, 2 forms of contraception: one highly effective, and one additional effective (barrier) measure of contraception without interruption 28 days prior to starting study treatment, during the study treatment, and for at least 90 days after the last dose of study treatment. Contraception requirements are detailed in section 9.5 and the current version of th
排除标准
- •Participants are excluded if any of the following criteria applies:
- •1. MM that does not express M-protein or FLC (i.e., non-secretory MM is excluded).
- •2. Documented active systemic amyloid light chain amyloidosis.
- •3. Active plasma cell leukemia.
- •4. Clinical evidence of central nervous system or pulmonary leukostasis, disseminated intravascular coagulation, or CNS MM.
- •5. Red Blood Cell transfusions and blood growth factors within 14 days of C1D1.
- •6. Radiation, chemotherapy, or immunotherapy or any other anticancer therapy or plasmapheresis within 2 weeks prior to C1D1, and radio-immunotherapy within 6 weeks prior to C1D1. Patients on long-term glucocorticoids during Screening do not require a washout period. Prior radiation is permitted for treatment of fractures or to prevent fractures as well as for pain management.
- •7. Treatment with an investigational anti-cancer therapy within 4 weeks prior to C1D1, last infusion with CAR-T cell therapy within 12 weeks prior to C1D1.
- •8. Treatment with granulocyte colony-stimulating factor (G-CSF) within 4 weeks prior to C1D1.
- •9. History of Grade =2 pneumonitis, active autoimmune disease, or persistent immune-mediated toxicity caused by immune checkpoint inhibitor therapy of Grade =2 with the exception of residual endocrinopathy adequately substituted, vitiligo, Type 1 diabetes mellitus, or psoriasis not requiring systemic therapy.
- •10. Active neuropathy >Grade 2 (CTCAE v5.0). or Grade = 2 neuropathy with pain at Screening (within 28 days prior to C1D1).
- •11. History of life-threatening toxicity related to prior immune therapy or any toxicity that resulted in permanent discontinuation of prior immune therapy.
- •12. Prior autologous stem cell transplantation < 3 month, or allogeneic stem cell transplantation < 12 months prior to C1D1.
- •13. Active graft versus host disease after allogeneic stem cell transplantation.
- •14. Major surgery within 4 weeks prior to C1D1.
- •15. Active, unstable cardiovascular function:
- •a. Symptomatic ischemia, or uncontrolled angina within the past 6 months
- •b. Myocardial infarction within 3 months prior to C1D1
- •c. Uncontrolled, clinically significant conduction abnormalities
- •d. Stroke/transient ischemic attack within 1 year prior to C1D1.
- •e. History of other clinically significant heart disease (e.g., cardiomyopathy, congestive heart failure with NYHA Class III-IV, pericarditis, significant pericardial effusion, or myocarditis)
- •f. Ejection fraction < 50% at Screening determined by echocardiogram or other approved method of evaluation
- •g. ECG with corrected QT interval (QTcF) of > 470 milliseconds or any clinically significant abnormal electrocardiogram (ECG) finding at Screening.
- •16. Prior history of malignancies, other than MM, unless the subject has been free of the disease for = 5 years with the exception of the following noninvasive malignancies:
- •a. Basal cell carcinoma of the skin
- •b. Squamous cell carcinoma of the skin
- •c. Carcinoma in situ of the cervix
- •d. Carcinoma in situ of the breast
- •e. Incidental histological findings of prostate cancer such as T1a or T1b using the Tumor/Node/Metastasis (TNM) classification of malignant tumors or prostate cancer that is curative
- •17. Uncontrolled active infection requiring systemic antibiotics, antivirals, or antifungals within 14 days prior to first dose.
- •18. Known infection with human immunodeficiency virus (HIV). Testing is not required for eligibility.
- •19. Known active infection with hepatitis B (surface antigen); or infection with hepati
研究者
相似试验
未知
1 期
Phase I Study of EOS789Healthy volunteerJPRN-jRCT2080222940Chugai Pharmaceutical Co., Ltd.112
进行中（未招募）
1 期
ONO-4578-04:ONO-4578 Phase 1 Studymetastatic pancreatic cancerJPRN-jRCT2031200286Hirashima Yoshinori60
进行中（未招募）
1 期
ONO-4578-03:ONO-4578 Phase 1 StudyJPRN-jRCT2051200096Hirashima Yoshinori30
已完成
3 期
AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH EARLY STAGE RELAPSING REMITTING MULTIPLE SCLEROSISThis study will evaluate the effectiveness and safety of ocrelizumab in early stage relapsing-remitting multiple sclerosis (RRMS) patients.non-small cell lung cancerLBCTR2020033434F. HOFFMANN-LA ROCHE LTD6
招募中
不适用
A single-blind and crossover study examining the efficacy of intranasal oxytocin administration for social impairments in subjects with pervasive developmental disordersPervasive developmental disordersJPRN-UMIN000005809Department of Neuropsychiatry, Showa University School of Medicine60